Oxford BioMedica plc · LSE:OXB
Oxford BioMedica — Investor Presentation (November 2016)
19 slides from Oxford BioMedica's investor presentation, November 2016
Slide 1: The LentiVector Company
The LentiVector® Company November 2016
Slide 2: Forward-looking statements
Forward-looking statements This presentation does not constitute an offer to sell or a solicitation of offers to buy Ordinary Shares (the “Securities”). Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions 2 Cohort expressed
Slide 3: Gene and Cell Therapy Company With a Leading Lentiviral Vector Delivery Platform
Gene and Cell Therapy Company With a Leading Lentiviral Vector Delivery Platform (LentiVector®) Gene and cell therapy expected to grow into a multi-billion US$ sector over the next 5-10 years1 Cohort2 Dose 1 Administration 3 months (UPDRS) 6 months (UPDRS) • Upcoming product launches: Strimvelis (GS
Slide 4: Oxford BioMedica, the LentiVector Company – at a glance
Oxford BioMedica, the LentiVector® Company – at a glance • 20 years’ experience • Formed out of Oxford University in 1996 – specialising in lentiviral products Cohort • 2 First to Dose administer a lentiviral Administration vector in vivo 3 months (UPDRS)(both6 months the (UPDRS) brain and1 year the
Slide 5: OXB active in both in vivo and ex vivo Programs
OXB active in both in vivo and ex vivo Programs In vivo development Ex vivo development Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Max. up to 30% Max. up to 50% Max. up to 44% Max. up to 30% 2, n
Slide 6: Leveraging Our LentiVector Delivery Platform
Leveraging Our LentiVector® Delivery Platform Partners’ Programmes OXB products via spin out or Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) out-licence 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Exposure to • Process developmentMax.fees up
Slide 7: Oxford BioMedica CAR-T partnership
Oxford BioMedica CAR-T partnership Overview Achievements to date • Non-exclusive Cohort2 Dose licence to Administration OXB’s IP: • Multiple Process 3 months (UPDRS) A CTL019 6 months (UPDRS) batches 1 year (UPDRS) supplied 2 years to Novartis (UPDRS) 1, n=3 1x Original Mean 27% since October 30% fo
Slide 8: Examples of companies conducting clinical trials with lentiviral vectors
Examples of companies conducting clinical trials with lentiviral vectors Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Max. up to 30% Max. up to 50% Max. up to 44% Max. up to 30% 2, n=3 2x Original
Slide 9: Products, IP and Facilities
Products, IP and Facilities
Slide 10: Products Pipeline
Products Pipeline Oxford BioMedica has an interest in many gene and cell therapy projects and our integrated platform technology is instrumental in the following wholly-owned and partnered / royalty-bearing programmes Research/ Product Cohort2 Indication Dose Administration Phase I 3 months Phase I/
Slide 11: Proprietary R&D Activity
Proprietary R&D Activity In-house Product Discovery/Research – Technical developments – continuous providing a flow 2 Cohort Dose of new product Administration 3 months (UPDRS)improvement opportunities of the 1LentiVector 6 months (UPDRS) year (UPDRS) ® platform 2 years (UPDRS) 1, n=3 1x Original Me
Slide 12: LentiVector Platform IP
LentiVector® Platform IP Expiration 2017/2018 2021/2023 2029 2034 Beyond Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Max. up to 30% Milestones Max. up to 50% & Royalties in 3rd party Max. up to 44
Slide 13: Oxford BioMedica Facilities in the UK
Oxford BioMedica Facilities in the UK Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Max. up to 30% Max. up to 50% Max. up to 44% Max. up to 30% 2, n=3 2x Original Mean 28% Mean 34% Mean 29% - Harrow
Slide 14: State-of-the-art Bioprocessing Facilities (Oxford, UK)
State-of-the-art Bioprocessing Facilities (Oxford, UK) Two separate bioprocessing sites Laboratories (2,136m2/22,992ft2) (total clean rooms 1,200m2/12,917ft2 ) Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% M
Slide 15: Future Vision and Summary
Future Vision and Summary
Slide 16: Potential Near-term Catalysts (Next 12 Months)
Potential Near-term Catalysts (Next 12 Months) • Novartis catalysts • Novartis CTL-019 study results Cohort2 • Novartis Dose CTL-019 BLA submission Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% • Milestones and
Slide 17: Vision of Oxford BioMedica – by end 2018
Vision of Oxford BioMedica – by end 2018 Core LentiVector® R&D Partnerships and Licences Bioprocessing Core LentiVector® R&D Bioprocessing Novartis • CTL019 3 months launched Facilities2operating at, New Cohort2product candidates OXB-102 Dose Administration (UPDRS) 6 months (UPDRS) 1 year (UPDRS) Fa
Slide 18: Summary: A Leading Gene and Cell Therapy Company
Summary: A Leading Gene and Cell Therapy Company • Gene and cell therapy is predicted to grow into a multi-billion US$ sector Cohort2 Dose 1 over the next 5-10 Administration years 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20%
Slide 19: Contact Us
Contact Us Oxford BioMedica plc Windrush Court Transport Way Oxford OX4 6LT John Dawson, CEO Tel: +44 (0) 1865 783 000 enquiries@oxfordbiomedica.co.uk www.oxfordbiomedica.co.uk
Oxford BioMedica — Investor Presentation (November 2016) on 6ix